Want to see ELVN full AI Analyst Report?
ELVN Stock Chart & Stats
$48.11
$0.01(0.04%)
At close: 4:00 PM EST
$48.11
$0.01(0.04%)
Day’s Range― - ―
52-Week Range$14.79 - $52.39
Previous CloseN/A
Volume37.78K
Average Volume (3M)1.92M
Market Cap
$3.56B
Enterprise Value$2.60B
Total Cash (Recent Filing)$452.40M
Total Debt (Recent Filing)$302.00K
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 19, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding71,438,280
10 Day Avg. Volume2,489,421
30 Day Avg. Volume1,917,746
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.34K
Enterprise Value/Ebitda-26.38
Forecast
1Y Price Target
$64.56Price Target Upside34.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong, Low-debt Balance SheetMinimal leverage and a substantially larger equity base provide durable financial optionality to fund clinical programs and strategic choices. Over the next several months this reduces short-term solvency risk, supports partnership negotiations, and allows management to pursue pivotal trials without immediate refinancing pressure.
Positive Phase 1 Data And FDA AlignmentRobust early efficacy and a favorable safety profile, combined with FDA alignment on Phase 3 dose and design, materially reduce regulatory and development risk. This durable clinical progress increases the probability of a successful pivotal study, enhances partner interest, and raises the programme's long-term commercial optionality.
Material Capital Raise To Extend RunwayA large, successful equity raise meaningfully strengthens near-term financing capacity to complete late-stage development and pivotal trials. Over the coming months, this reduces the probability of disruptive emergency financings, enabling deliberate trial execution and strategic partnership or commercialization planning.
Bears Say
Pre-revenue With Widening Operating LossesAbsent product revenue, growing operating losses mean the capital base is not producing returns and the business remains dependent on external funding. Over a multi-month horizon this structural loss profile heightens execution risk: failed trials or delays would prolong losses and force more dilutive financing.
Sustained Negative Free Cash Flow / Cash BurnPersistent negative FCF requires repeated capital markets access and constrains strategic flexibility. Even with recent proceeds, variable and elevated burn means runway is tied to trial timelines; any delays or expanded programs will likely increase financing needs and shareholder dilution over time.
Dependence On Equity Financings And Dilution RiskManagement's reliance on share issuance and an expanded authorization creates a persistent dilution channel. Over months, this structural dependence on equity markets can depress per-share economics and reduce incentives for long-term holders if development timelines slip or additional financings become necessary.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics, Inc.’s price range in the past 12 months?
Enliven Therapeutics, Inc. lowest stock price was $14.79 and its highest was $52.39 in the past 12 months.
What is Enliven Therapeutics, Inc.’s market cap?
Enliven Therapeutics, Inc.’s market cap is $3.56B.
When is Enliven Therapeutics, Inc.’s upcoming earnings report date?
Enliven Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 42 days.
How were Enliven Therapeutics, Inc.’s earnings last quarter?
Enliven Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.444 by $0.064.
Is Enliven Therapeutics, Inc. overvalued?
According to Wall Street analysts Enliven Therapeutics, Inc.’s price is currently Undervalued.
Does Enliven Therapeutics, Inc. pay dividends?
Enliven Therapeutics, Inc. does not currently pay dividends.
What is Enliven Therapeutics, Inc.’s EPS estimate?
Enliven Therapeutics, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Enliven Therapeutics, Inc. have?
Enliven Therapeutics, Inc. has 71,438,280 shares outstanding.
What happened to Enliven Therapeutics, Inc.’s price movement after its last earnings report?
Enliven Therapeutics, Inc. reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.444. Following the earnings report the stock price went up 1.142%.
Which hedge fund is a major shareholder of Enliven Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.56 (34.18% Upside)
$64.56 (34.18% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $51.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 26.7%
Last 30 Days ▲ 26.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.24%
12-Months-Change
Fundamentals
Return on Equity
-21.04%
Trailing 12-Months
Asset Growth
53.63%
Trailing 12-Months
Company Description
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$64.56
▲(34.18% Upside)
Technical Analysis
Sarepta Therapeutics
―
Viridian Therapeutics
―
―
Intellia Therapeutics
―
AbCellera Biologics
―
Ownership Overview
23.11% Insiders
14.26% Mutual Funds
53.88% Other Institutional Investors
0.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---